Literature DB >> 29219892

Toxicity of Vincristine Combined With Posaconazole in Children With Acute Lymphoblastic Leukemia.

Esra Pekpak1, Talia İleri, Elif İnce, Mehmet Ertem, Zümrüt Uysal.   

Abstract

BACKGROUND: Vincristine (VCR) is one of the main drugs of acute lymphoblastic leukemia (ALL) treatment. Azole antifungal medications are used for treatment or prophylaxis of invasive fungal infections in acute leukemia. Coadministration of these drugs increases the risk of VCR toxicity. OBSERVATIONS: We presented a girl with ALL using posaconazole prophylaxis. She developed VCR toxicity that included tubulopathy, high blood pressure, neuropathic pain, difficulty walking, diffuse muscular weakness, constipation, abdominal pain.
CONCLUSIONS: There are limited data in children with ALL for posaconazole prophylaxis. We recommend that VCR side effects should be evaluated by careful monitoring of the patients who are on this combination therapy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29219892     DOI: 10.1097/MPH.0000000000001022

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections.

Authors:  Alexander F A D Schauwvlieghe; Jochem B Buil; Paul E Verweij; Rogier A S Hoek; Jan J Cornelissen; Nicole M A Blijlevens; Stefanie S V Henriet; Bart J A Rijnders; Roger J M Brüggemann
Journal:  Mycoses       Date:  2019-12-15       Impact factor: 4.377

2.  Posaconazole aggravates vincristine-related hypertension in children with acute lymphoblastic leukemia: a case report.

Authors:  Chao Lin; Guohua Chen; Junbin Huang; Yucai Cheng; Yahong Xu; Airun Zhang; Hongman Xue; Chun Chen
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

3.  Benefits of risk-adapted and mould-specific antifungal prophylaxis in childhood leukaemia.

Authors:  Andreas Meryk; Gabriele Kropshofer; Julia Hutter; Josef Fritz; Christina Salvador; Cornelia Lass-Flörl; Roman Crazzolara
Journal:  Br J Haematol       Date:  2020-07-04       Impact factor: 8.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.